title: Efficacy of percutaneous vocal fold injections for benign laryngeal lesions: Prospective multicenter study.
abstract: CONCLUSIONS
  Percutaneous steroid injection (PSI) may be a useful alternative modality for treatment of benign vocal fold lesions.
  
  
  OBJECTIVE
  When patients refuse general anesthesia or voice therapy for benign vocal fold diseases (Reinke's edema, vocal polyp, nodule, and scarring), there are no other options available. We conducted an analysis of the effects of PSI as an alternative treatment for benign vocal fold diseases.
  
  
  METHODS
  From October 2008 to March 2010, 130 patients with benign vocal fold disease who refused general anesthesia or showed no response to voice therapy underwent PSI. From this group, the present study included 115 patients who completed the evaluation before PSI and at the first and third month after PSI and also an additional 25 patients who completed evaluation at the sixth month after PSI.
  
  
  RESULTS
  Among 115 patients in the study, 40 cases (34.8%) showed complete remission and 57 cases (49.6%) showed partial remission. As a result, overall improvement rates were 84.4%. Almost all objective and subjective parameters showed statistical improvement at the first and third month after PSI (p < 0.05). Jitter and all subjective parameters maintained statistical improvement until the sixth month. No severe complications, such as fold atrophy, were observed.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Gachon University of Medicine & Science, Graduate School of Medicine, Incheon, Korea.
authors.forename: Joo-Hyun
authors.initials: JH
authors.lastname: Woo
authors.forename: Dong-Young
authors.initials: DY
authors.lastname: Kim
authors.forename: Jae-Wook
authors.initials: JW
authors.lastname: Kim
authors.forename: Eun-A
authors.initials: EA
authors.lastname: Oh
authors.forename: Seung-Won
authors.initials: SW
authors.lastname: Lee
mesh_terms: D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007818:Laryngeal Diseases / Q000628:therapy*; D011446:Prospective Studies; D012074:Remission Induction; D016312:Treatment Refusal; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014827:Vocal Cords / Q000187:drug effects*; D014833:Voice Quality
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide